



Hans-Jürgen Machulla | Ehab Al-Momani | Noeen Malik

The PET Method

Tracer Principle and Radiochemistry



Steinbeis-Transferzentrum
Institute for Radiopharmacy

Hans-Jürgen Machulla, Ehab Al-Momani, Noeen Malik
The PET Method

Hans-Jürgen Machulla, Ehab Al-Momani, Noeen Malik

The PET Method

Tracer Principle and Radiochemistry

Imprint

© 2016 Steinbeis-Edition

All rights reserved. No part of this book may be reprinted, reproduced or utilised in any form by any electronic, mechanical or other means now known or hereafter invented, including photocopying, microfilming and recording or in any information storage or retrieval system without written permission from the publisher.

Hans-Jürgen Machulla, Ehab Al-Momani, Noeen Malik
The PET Method. Tracer Principle and Radiochemistry

1st edition, 2016 | Steinbeis-Edition, Stuttgart
ISBN 978-3-95663-081-1

Layout: Steinbeis-Edition
Cover picture: shutterstock.com / isak55
Production: Frick Kreativbüro & Onlinedruckerei e.K., Krumbach | Printed in Germany

Steinbeis is an international service provider in entrepreneurial knowledge and technology transfer. The Steinbeis Transfer Network is made up of about 1,000 enterprises. Specialized in chosen areas, Steinbeis Enterprises' portfolio of services covers research and development; consulting and expert reports as well as training and employee development for every sector of technology and management. Steinbeis Enterprises are frequently based at research institutions, especially universities, which are constituting the Network's primary sources of expertise. The Steinbeis Network comprises around 6,000 experts committed to practical transfer between academia and industry. Founded in 1971, the Steinbeis-Stiftung is the umbrella organization of the Steinbeis Transfer Network. It is headquartered in Stuttgart, Germany. Steinbeis-Edition publishes selected works mirroring the scope of the Steinbeis Network expertise.

173977-2016-10 | www.steinbeis-edition.de

*to
our families
and in particular
our youngsters
Alexander, Desiree, Lamar and Yousef*

Preface

In medicine beside CT and MRT, Positron Emission Tomography (PET), combined as PET/CT or PET-MRT, is one of the *Molecular Imaging* modalities. Many colleagues and authors have continuously been involved in new developments within both research and clinical application as annually presented in the corresponding meetings in Europe and US. Yet, colleagues in many neighboring disciplines are still not aware of those developments. There are even large areas in which the PET Method has not really been recognized at all during the past three decades.

Among those imaging techniques, PET is more than just another procedure, it is a method exhibiting a unique role due to the fact of assessing metabolic processes. The PET radionuclides, which are typically applied, have short half-lives. That means, the compounds labeled with such radionuclides have a very low mass like 10^{-6} g and even less, as administered in a whole body dose. Thus, the metabolic processes to be studied are not altered while ongoing within the organism. Therefore, these compounds (tracers) allow to “*trace*” the biochemical processes of interest directly within the organism. In principal, the PET Method gives the possibility of a direct transfer from the *in-vitro* to the *in-vivo* level that means the translation from the static to the dynamic biological system. Therefore, *in-vivo* examinations are performed in animal models and can be transferred to humans directly in a subsequent study.

Among the PET radionuclides, carbon-11 is well suited for labeling any molecule without changing the biological properties. That has opened an outstanding possibility in drug research. Examinations in animal models show directly the kinetics of the metabolic turnover, provided that differences in circulations are considered. That approach, however, is practically not in use in drug development. Despite a few examples, it must clearly be stated that in pharmaceutical research and drug development, the PET Method is not used. In oncology, clinical trials are usually not controlled for multi-drug resistance (MDR). So the failure of such a trial may be due to the bad quality of the new drug, the presence of MDR or both. During the past twenty years even direct discussions with responsible CEOs never changed the route of drug development.

In general, follow-up studies in therapy and control of treatment strategies are immediately realized by applying the PET Method. In therapy of breast or prostate tumors, for example, response can be determined after two weeks and strategy of treatment may be changed in case of nonresponding patients. In neurology and psychiatry a typical example is the treatment of depression by SSRIs. That may directly be controlled by PET measurement of occupancy of serotonin transporter. In particular, the application of the PET Method in the field of brain receptors has opened a wide field in neurology and psychiatry.

The PET Method is slowly, but continuously developing and exhibits a driving force and its application remains a challenging and rewarding task in scientific and medical research. That gave the impact for this book to describe and explain applications and progress of the PET Method to students and colleagues in the neighboring disciplines within scientific and medical research.

May 2016
The Authors

Acknowledgement

This book project was completed with the help and support of many colleagues and friends what we keep gratefully to acknowledge. We also are very thankful to Prof. A. Buck, *Clinic for Nuclear Medicine*, and Prof. S. Samnick, *Exp. Nuclear Medicine*, at Univ. Würzburg for their stimulating discussions and continuous encouragement.

In particular, we like to thank Prof. Ambros J. Beer, *Clinic for Nuclear Medicine* at Univ. Ulm, Prof. Bernd Pichler, *Preclinical Imaging and Radiopharmacy* at Univ. Tübingen and Prof. Hans-Jürgen Wester, *Pharmaceutical Radiochemistry* at TU Munich for their active support by providing the figures which are essential for the book.

Our special thanks are due to Rebecca Maxey, Director of communications at the Society of Nuclear Medicine and Molecular Imaging for the generosity of granting the permissions for the figures published in different editions of the Journal of Nuclear Medicine.

The authors are gratefully indebted to the Edition of the Steinbeis Foundation for Technology Transfer in Stuttgart, i. e. Yvonne Hübner and Deborah Richter for their well-structured handling and organizing this book project and, in particular, Hanna Runge for taking care of the layout of the graphics both in general and in all the details.

Last but not least, we thank our families for their encouraging support, love and patience to keep continuing and actually finishing this book.

The Authors

Table of Content

Preface	VI
Acknowledgement	VIII
Aim	1
1 Introduction	2
1.1 The Tracer Principle	5
1.2 Application in vitro and in vivo	6
1.2.1 Radiopharmaceutical concepts for application in vivo.....	9
1.2.2 Quantification of glucose metabolism	11
1.3 Radionuclides in tracers for PET and SPECT imaging.....	14
1.4 Measurement by PET and SPECT	19
1.5 Low amount of tracer not effecting metabolic functions.....	22
1.6 Specific activity.....	24
2 PET Tracers	26
2.1 Carbon-11	26
2.1.1 Production of carbon-11	28
2.1.2 [¹¹ C]-Synthons for radiosynthesis.....	29
2.1.2.1 Formation of ¹¹ CH ₃ I	32
2.1.3 Radiosynthesis of [¹¹ C]-tracers.....	33
2.1.3.1 Radiosynthesis with synthons produced within the target	33
2.1.3.2 Radiosynthesis with synthons produced subsequently	35
2.1.3.3 Labeling by [¹¹ C]-alkylation.....	41
2.2 Fluorine-18.....	44
2.2.1 Production of fluorine-18.....	46
2.2.2 Reactions for radiofluorination	47
2.2.2.1 Labeling by electrophilic reactions	47
2.2.2.2 Nucleophilicity of [¹⁸ F]fluoride for nucleophilic substitution ...	49

2.2.2.3	Nucleophilic aliphatic substitution	51
2.2.2.4	Nucleophilic aromatic [¹⁸ F]fluorination	54
2.2.2.5	[¹⁸ F]-Synthons.....	57
2.3	Gallium-68 (⁶⁸ Ga)	67
2.3.1	Availability of ⁶⁸ Ga.....	67
2.3.2	Radiochemistry.....	68
2.3.3	Radiosynthesis.....	69
3	SPECT Tracers	76
3.1	Technetium-99m	76
3.1.1	Procedure for providing technetium-99m	76
3.1.2	Radiolabeling.....	79
3.1.3	^{99m} Tc-Labeled compounds as radiopharmaceuticals for SPECT measurement.....	80
3.2	Radioiodine	84
3.2.1	Role of radioiodine in radiopharmaceutical concepts.....	86
3.2.2	Methods of production	89
3.2.3	Radiosynthesis.....	90
3.2.3.1	Nucleophilic substitutions of halogens.....	91
3.2.3.2	Direct electrophilic radioiodination and electrophilic demetallation.....	93
3.2.3.3	Prosthetic groups in labeling with radioiodine	97
4	Applications in life sciences.....	99
4.1	FDG for the assay of glucose metabolism	102
4.2	Assay of oxygen metabolism and role of movement.....	105
4.3	PET imaging of brain tumors	106
4.4	Imaging of tumor growth by FLT	111
4.5	Hypoxia imaging.....	114
4.6	Cardiology	120
4.7	Prostate cancer	123

4.8	Imaging of patients with Alzheimer's disease (AD)	129
4.9	Determination of apoptosis in consequence of chemotherapy.....	134
4.10	Assay of neurotransmitter function in brain.....	137
4.11	Drug evaluation in pharmaceutical research.....	142
5	Current situation and perspectives of the PET Method.....	146
5.1	Current situation	146
5.2	Fields of application	147
5.2.1	Oncology.....	147
5.2.2	Neurology and psychiatry	148
5.2.3	Drug development	148
5.3	Technological and scientific improvements	150
5.3.1	Technical progress	150
5.3.2	Routine production of tracers.....	151
5.3.3	Biotechnology and coordination chemistry	152
5.3.4	Interdisciplinarity.....	153
5.4	Perspectives	155
	Further Readings.....	158
	Notes of References	160
	References.....	164
	List of Abbreviations	192
	List of Copyright Permissions	196
	Table of Figures.....	198
	List of Tables.....	206
	Index.....	207
	Authors	220

Aim

The PET Method plays a unique role because it makes it possible to monitor ongoing biochemical processes within the organism by a registration outside of the body. This ability is directly attributed to radioactively labeled compounds, which allow PET registration to provide a highly specific and selective assessment of the metabolic function of interest. The combination of PET measurements with CT or MRT localizes the registered metabolic alterations anatomically, which is necessary in clinical applications.

In general, PET is more than an imaging modality: it is a biochemical method based on the *Tracer Principle*, and most importantly, it is applied *in vivo*. A pre-requisite is the radio chemistry for radionuclide production, radiosynthesis and radioanalytics. Taken together, for applications in experimental, i. e., preclinical research areas and clinical diagnostics, the PET Method opens new dimensions of opportunities, for which impressive examples exist.

In the past, physical, technical and scientific methods and procedures had to be handled by highly specialized and experienced radiochemists and other experts, but meanwhile the tools, methods and procedures have become so well developed that the preparations for the PET Method are standard procedures in any radiochemical laboratory. This development is particularly well illustrated by the fact that, as self-shielded units, cyclotrons can be installed in any room or a building without special constructions.

It is the aim of this book to bring together

- the potential of the *Tracer Principle* applied in the PET Method,
- the basics of radiochemistry, offering a versatile array of radiosynthetic procedures and
- important examples illustrating the broad spectrum of experimental and clinical applications.